UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (date of earliest event reported): June 5, 2008
|
Nevada
|
0-9410
|
90-0031917
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
7327
Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address
of Principal Executive Offices)
(866) 594-5999
(Registrant’s
Telephone Number, Including Area Code)
Check the
appropriate box if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
On
June 3, 2008, the board of directors of Provectus Pharmaceuticals, Inc. (the
"Company") appointed Kelly M. McMasters, MD, PhD, to serve as a member of
the Board of Directors. A copy of the related press release is attached
hereto as Exhibit 99.1.
Dr. McMasters
received his undergraduate training at Colgate University prior to completing
the MD/PhD program at the University of Medicine and Dentistry of New Jersey,
Robert Wood Johnson Medical School and Rutgers University. He then completed the
residency program in General Surgery at the University of Louisville, and a
fellowship in Surgical Oncology at M.D. Anderson Cancer Center in Houston. He is
currently the Sam and Lolita Weakley Professor of Surgical Oncology at the
University of Louisville in Kentucky, a position he has held since 1996. Since
2005, he has chaired the Department of Surgery at the University of Louisville
and also has been Chief of Surgery at University of Louisville Hospital. Since
2000, he has also been Director of the Multidisciplinary Melanoma Clinic of the
James Graham Brown Cancer Center at the University of Louisville. His is an
active member of the surgery staff at the University of Louisville Hospital,
Norton Hospital and Jewish Hospital in Louisville. He is on the editorial boards
of the Annals of Surgical Oncology, Cancer Therapy and the Journal of Clinical
Oncology as well as an ad hoc reviewer for 9 other publications. He holds
several honors, chief among them is "Physician of the Year" awarded by the
Kentucky Chapter of the American Cancer Society. He is the author and principal
investigator (PI) of the Sunbelt Melanoma Trial, a multi-institutional study
involving 3500 patients from 79 institutions across North America and one of the
largest prospective melanoma studies ever performed. He has been a PI, Co-PI or
local PI in over thirty clinical trials ranging from Phase 1 to Phase 3. For the
past 12 years he has also directed a basic and translational science laboratory
studying adenovirus-mediated cancer gene therapy funded by the American Cancer
Society and the National Institutes of Health (NIH).
Item 9.01 Financial Statements and Exhibits
Exhibit
Number Description of
Exhibit
-----------
-----------------------------
99.1
Press Release of Provectus Pharmaceuticals, Inc. dated June 3, 2008.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| Provectus Pharmaceuticals, Inc. | |||
|
Date:
June 5, 2008
|
By:
|
/s/ Peter Culpepper | |
| Title: Chief Financial Officer | |||